KPRX · XBRL financial data

Kiora Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KPRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	0	16,020	0
Revenue from contracts with customers	12	0	—	—	—	—
Research and development	3,566	5,350	3,449	4,027	7,842	10,780
General and administrative	4,659	5,324	8,278	4,663	5,542	5,745
Total operating expenses	8,225	14,236	12,310	12,587	11,510	12,831
Operating income (loss)	(6,869)	(14,236)	(12,310)	(12,587)	4,510	(12,831)
Interest income	23	1	57	174	1,253	894
Interest expense	4	7	9	11	21	20
Other income (expense)	—	—	(14)	29	26	(160)
Income tax expense (benefit)	12	(193)	(113)	90	2,065	(1,282)
Net income (loss)	(8,092)	(13,771)	(13,584)	(12,514)	3,595	(10,835)
Earnings per share, basic‡ USD per share	(536.40)	(514.80)	(166.95)	(24.21)	0.93	(2.60)
Earnings per share, diluted‡ USD per share	(536.40)	(514.80)	(166.95)	(24.21)	0.87	(2.64)
Weighted average shares, basic‡ thousands of shares	13	27	81	538	3,873	4,167
Weighted average shares, diluted‡ thousands of shares	13	27	81	538	4,125	4,104

‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (September 2022); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-9.000009000009 stock split (June 2024); filings made before it reported them unadjusted.
† Share count changed about 6x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 14x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KPRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,186	7,855	5,965	2,455	3,792	8,697
Short-term investments	—	—	—	0	23,000	8,393
Accounts receivable	—	—	—	0	601	1,523
Prepaid and other current assets	450	607	343	233	2,042	1,142
Total current assets	1,810	8,991	7,681	4,738	29,706	21,748
Property and equipment, net	31	74	55	8	5	92
Right-of-use asset	84	209	117	107	57	286
Goodwill	3,485	0	0	—	—	—
Total assets	15,158	20,130	18,678	13,712	36,484	24,253
Accounts payable	435	161	1,008	206	416	1,060
Accrued liabilities	1,289	1,330	1,836	1,381	4,589	2,407
Total current liabilities	1,772	1,610	3,272	1,634	6,009	3,631
Long-term debt	278	—	—	—	—	—
Lease liability, non-current	36	91	0	60	34	204
Total liabilities	8,158	5,551	7,271	7,602	10,725	8,127
Accumulated deficit	(108,339)	(120,879)	(134,463)	(146,977)	(143,382)	(154,217)
Total stockholders' equity	7,000	14,579	11,408	6,110	25,760	16,127
Total liabilities and equity	15,158	20,130	18,678	13,712	36,484	24,253
Common shares outstanding (cover page)‡ thousands of shares	20	35	213	2,917	3,001	3,951

‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (September 2022); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-9.000009000009 stock split (June 2024); filings made before it reported them unadjusted.
† Share count changed about 6x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 14x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (KPRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(8,092)	(13,771)	(13,584)	(12,514)	3,595	(10,835)
Stock-based compensation	724	842	462	755	657	900
Depreciation and amortization	33	45	42	52	19	25
Net cash from operating activities	(7,317)	(10,675)	(10,428)	(9,557)	8,559	(9,961)
Purchases of property and equipment	20	64	0	0	6	111
Net cash from investing activities	(244)	(157)	6	0	(22,663)	14,427
Proceeds from issuing common stock	5,000	18,750	5,378	—	—	—
Proceeds from long-term debt	278	0	—	—	—	—
Net cash from financing activities	4,998	17,583	8,621	5,966	15,498	266
Net change in cash	(2,591)	6,669	(1,886)	(3,555)	1,337	4,905

† Share count changed about 6x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 14x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.